Keine Internetverbindung – die gespeicherte Version der Seite wird angezeigt.

Biomarin Pharmace…

USUSD
← Zum Screener

Biomarin Pharmaceutical Inc (US:BMRN) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 4. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.

Über das Unternehmen

Website
biomarin.com
Investor Relations
investors.biomarin.com/overview/default.aspx
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hauptsitz
NOVATO, United States
CEO
Jean Jacques Bienaime
Mitarbeiter
3 221
Gegründet
1997
Ausstehende Aktien
193.57 Mio. Stand 2026-07-28
Streubesitz
192.63 Mio.
Marktkapitalisierung
11.51 Mrd. USD
Insider
0.34%
Institutionelle Anleger
103.8%
Branche (SIC)
Pharmaceutical Preparations
Rechtsform
XTIQ
ISIN
US09061G1013
LEI
NSLL8ITTRR0J5HEMR848
Beschreibung

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Börsen und Ticker

BörseTickerWährungPreisTyp
US USA StocksBMRNUSD57.54 +0.63%Stammaktie
LSE London Stock Exchange0HNCUSD60.5 +0.00%Stammaktie
MI Borsa Italiana (Milan)1BMRNEUR54.34 -3.21%Stammaktie
VI Vienna Stock ExchangeBMRNEUR52.96Stammaktie

Kurs über 3 Monate

Tag mit Kursanstieg Tag mit Kursrückgang Ex-Dividenden-Tag ZahltagTag mit der Maus berühren / antippen — Eröffnungs-, Schluss-, Höchst- und Tiefstkurs

Dividenden

Keine Dividendenzahlungen gefunden (geprüft 06.10.2026). Das Unternehmen schüttet wahrscheinlich keine Dividenden aus.

Anzeige

Größte Anteilseigner

InhaberAnteilAktienBerichtsdatum
Blackrock Inc.10.56%20.45 Mio.2026-06-30
Dodge & Cox Inc.7.67%14.84 Mio.2026-06-30
Primecap Management Comp…7.33%14.19 Mio.2026-06-30
Dodge & Cox Funds-Dodge…5.05%9.77 Mio.2026-06-30
Vanguard Capital Managem…4.52%8.74 Mio.2026-06-30
Vanguard Portfolio Manag…4.47%8.65 Mio.2026-06-30
NORGES BANK4.24%8.21 Mio.2026-06-30
State Street Corporation4.03%7.8 Mio.2026-06-30
Viking Global Investors,…3.93%7.62 Mio.2026-06-30
iShares Trust-iShares Co…3.5%6.77 Mio.2026-08-31
VANGUARD INDEX FUNDS-Van…3.17%6.14 Mio.2026-06-30
Vestal Point Capital, LP3.11%6.03 Mio.2026-06-30
AQR Capital Management,…2.94%5.7 Mio.2026-06-30
VANGUARD HORIZON FUNDS-V…2.67%5.17 Mio.2026-06-30
VANGUARD CHESTER FUNDS-V…2.57%4.97 Mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.29%4.43 Mio.2026-06-30
Fidelity Contrafund1.47%2.84 Mio.2026-07-31
Capital World Growth & I…1.33%2.58 Mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.32%2.55 Mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%2.22 Mio.2026-06-30
HARDY ALEXANDER (Chief E…≈0.11%218 8872026-03-16
MEIER RICHARD A (Directo…≈0.07%126 9262025-12-30
MUELLER BRIAN R (Chief F…≈0.06%125 4312026-03-16
GUYER CHARLES GREG (Chie…≈0.04%85 8332026-03-16
DAVIS GEORGE ERIC (Offic…≈0.03%61 0032026-09-02
FRIBERG GREGORY R (Offic…≈0.03%51 8182026-05-07
HOMBACH ROBERT J. CPA (D…≈0.03%49 3602026-06-02
DERE WILLARD H (Director…≈0.02%46 4402026-06-02
HUBBARD CRISTIN (Officer…≈0.02%44 7902026-03-16
ANDERSON ELIZABETH M (Di…≈0.02%41 9402026-06-02

Meldungen an die Aufsicht

DatumAufsichtsbehördeEreignisDetails
2026-10-02ESMAоновлення даних інструментаISIN, майданчик HAND
2026-10-01SECінсайдерська подачаФорма 4
2026-09-30SECпоточний звітФорма 8-K